Supplementary Figures S1-S8 from Phosphocreatine Promotes Epigenetic Reprogramming to Facilitate Glioblastoma Growth Through Stabilizing BRD2

Lishu Chen,Qinghui Qi,Xiaoqing Jiang,Jin Wu,Yuanyuan Li,Zhaodan Liu,Yan Cai,Haowen Ran,Songyang Zhang,Cheng Zhang,Huiran Wu,Shuailiang Cao,Lanjuan Mi,Dake Xiao,Haohao Huang,Shuai Jiang,Jiaqi Wu,Bohan Li,Jiong Xie,Ji Qi,Fangye Li,Panpan Liang,Qiuying Han,Min Wu,Wenchao Zhou,Chenhui Wang,Weina Zhang,Xin Jiang,Kun Zhang,Huiyan Li,Xuemin Zhang,Ailing Li,Tao Zhou,Jianghong Man
DOI: https://doi.org/10.1158/2159-8290.26467117
2024-01-01
Abstract:Supplementary Figures S1 shows that GSCs produce high levels of phosphocreatine through upregulating CKB. Supplementary Figures S2 shows that ZEB1 promotes CKB transcription in GSCs. Supplementary Figures S3 shows that knockdown of CKB impedes GBM growth. Supplementary Figures S4 shows that disruption of phosphocreatine production impedes GBM growth. Supplementary Figures S5 shows that cCr treatment shows no side effect on mice. Supplementary Figures S6 shows that phosphocreatine binds to BRD2 and inhibits its ubiquitin mediated proteasomal degradation. Supplementary Figures S7 shows that phosphocreatine promotes chromosome segregation and GSC proliferation through BRD2 mediated transcription. Supplementary Figures S8 shows that disruption of phosphocreatine biosynthesis by cCr improves JQ1 therapeutic efficacy in GBM.
What problem does this paper attempt to address?